On May 9, 2018, Sarepta Therapeutics, Inc. joined Parent Project Muscular Dystrophy for a webinar update to discuss PPMO, Sarepta’s next generation precision RNA-targeting therapeutic platform for use in Duchenne muscular dystrophy. Sarepta also introduced their planned innovative enhancements to the trial design for their actively enrolling Phase 1 clinical trial, 5051-101, for their PPMO exon 51 candidate (SRP-5051, NCT: 03375255), and outlined their plans for future development of additional exon targets.
* This webinar recording contains edits to content requested by the company.
by: Parent Project Muscular Dystrophy
